PM and DM are characterized clinically by weakness and low endurance of skeletal muscle. Other organs are frequently involved, suggesting that idiopathic inflammatory myopathies (IIMs) are systemic inflammatory diseases. Involvement of immune mechanisms in IIMs is supported by the presence of T cells, macrophages and dendritic cells in muscle tissue, by the presence of autoantibodies and by HLA-DR being a strong genetic risk factor. T cells may have direct and indirect toxic effects on muscle fibres, causing muscle fibre necrosis and muscle weakness, but the target of the immune reaction is not known. A newly identified T cell subset, CD28 null T cells, may have cytotoxic effects in the CD4 + and CD8 + T cell phenotype. These cells are apoptosis resistant and may contribute to treatment resistance. Several myositis-specific autoantibodies have been identified, but they are all directed against ubiquitously expressed autoantigens and the specificity of the T cell reactivity is not known. These autoantibodies are associated with distinct clinical phenotypes and some with distinct molecular pathways; e.g. sera from patients with anti-Jo-1 autoantibodies may activate the type I IFN system and these sera also contain high levels of B cell activating factor compared with other IIM subsets. The characterization of patients into subgroups based on autoantibody profiles seems to be a promising way to learn more about the specificities of the immune reactions. Careful phenotyping of infiltrating immune cells in muscle tissue before and after specific therapies and relating the molecular findings to clinical outcome measures may be another way to improve knowledge on specific immune mechanism in IIMs. Such information will be important for the development of new therapies.
Introduction
PM and DM are characterized clinically by weakness and low endurance of skeletal muscle and histopathologically by the presence of T cells, macrophages, dendritic cells, B cells and plasma cells in the muscle tissue. Autoantibodies are common and are present in up to 80% of patients [1, 2] . The presence of immune cells in muscle tissue together with the frequent presence of autoantibodies suggest that immune mechanisms are involved in the pathogenesis, which has implications for treatment of these diseases. Glucocorticoids in high doses form the basis of treatment, but their use is limited by the high frequencies of side effects. The clinical effect of glucocorticoid treatment also has a limited effect on muscle performance in many patients and some patients do not respond at all and have persisting inflammation in muscle tissue. Gaining increased knowledge of the pathophysiology, including the immune mechanisms in these diseases, is important to improve treatment. In this review we will discuss some novel insights into possible immune mechanisms in the adaptive immunity and potential differences in subsets of myositis based on the autoantibody profile and clinical phenotype of idiopathic inflammatory myopathies (IIMs).
Immune mechanisms in PM and DM
The strongest support for an immune-mediated myopathy is the presence of cellular infiltrates of both the adaptive and innate immune systems in muscle biopsies and the frequent presence of autoantibodies. Another support is that the major genetic risk factor in Caucasian patients with IIM is MHC class II genes, of which HLA-DR3 is a major risk factor, as the major role of the HLA-DR molecules is to present antigens to CD4 + T cells [3] .
A role of the adaptive immunity in pathogenesis was suggested with the first reports using immunohistochemistry to phenotype the inflammatory cells in muscle biopsies of patients with myositis describing both CD4 + and CD8 + T cells and B cells in the inflammatory cell infiltrates [4] . Two distinct patterns of inflammatory cellular infiltrates have been identified, suggesting two different immunemediated pathways involved in muscle inflammation; one with the inflammatory cell infiltrates primarily localized to the endomysium surrounding non-necrotic muscle fibres-endomysial infiltrates-and another primarily localized to the perimysium surrounding blood vessels-perivascular infiltrates. However, these patterns are not mutually exclusive and may sometimes occur together. The differences in the pattern of inflammation suggest that different immune mechanisms and different immune specificities may vary between different subsets of patients. However, with the conventional subgrouping based on clinical phenotypes, PM and DM may not always distinguish between the different immune phenotypes present in muscle tissue. Furthermore, treatment response varies within the subgroups of PM and DM, which might also suggest different molecular pathways. Together this heterogeneity emphasizes a need for new subphenotyping of patients that may identify more homogeneous subsets of myositis that are likely to share molecular pathways. This may be through subgrouping based on autoantibody profiles.
Autoantibodies
Interestingly over the last few years several myositisspecific autoantibodies (MSAs) have been identified [5] . To date a majority of patients with PM and DM has at least one MSA if sensitive techniques to identify autoantibodies are utilized ( Tyrosyl-tRNA synthetase Anti-Mi-2 Dermatomyositis, skin rashgood treatment response.
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Anti-SUMO-1 Skin manifestations before muscleinvolvement, and many experienced dysphagia. somewhat between the different anti-synthetase autoantibodies, interstitial lung disease (ILD) is the most consistent manifestation and is often present as an early sign of disease, indicating a role for the lungs in the pathogenesis of this subphenotype of patients ( Table 1 ). The anti-histidyl antibodies (anti-Jo-1) are the most frequent antisynthetase antibodies, found in 1520% of patients. Serum levels of anti-Jo-1 antibodies correlate with disease activity, which supports a role for the antibodies in disease mechanisms [9] . The targets of the tRNA synthetase autoantibodies are ubiquitous enzymes expressed within the cytoplasm, where they attach amino acids to their cognate tRNA. It is unclear how these ubiquitous enzymes become autoantigens and why particularly lungs and muscles become targets of the immune response in these myositis subsets. A small study including muscle biopsies from 11 patients with anti-Jo-1 antibodies suggested a predominating perimysial inflammation and muscle fibre pathology in perifascicular areas, but these observations need to be confirmed in a larger study [20] . The target of the anti-Jo-1 antibodies has been the subject of several investigations to understand the immune mechanisms. Interestingly, a proteolytically cleavable form of histidyltRNA synthetase is enriched in the lung and localized to the alveolar epithelium. Newly generated fragments led to maturation of dendritic cells into professional Further investigations are needed in order to understand the immune specificities in PM and DM. The characterization of patients into subgroups based on autoantibody profiles seems to be a promising way to learn more about the specificities of the immune reactions. Possibly different molecular pathways may be associated with different immune specificities, giving rise to different clinical features and treatment responses. of interest for treatment in refractory PM/DM patients, but more information is needed on the mechanisms of actions of these cells to develop therapies that target these cells. T cells may contribute to pathogenesis not only by causing direct cytotoxicity, but also by shifting the immune balance from suppressive to proinflammatory. IL-17 mRNA was expressed in biopsy samples of inflammatory myopathies, implicating another T cell subset, Th17 [47] . Th17 cells produce IL-17, which has a role in the migration, differentiation and maturation of inflammatory cells. It was further shown that IL-17 in combination with IL-1b led to increased IL-6, HLA class I, CCL20 and nuclear factor (NF)-kB production in myoblasts [48] . These data indicate that Th17 cells may contribute to muscle damage and chronic inflammation [49] . A disturbed T cell homeostasis could be due to a deficit in FOXP3 + regulatory T cells (Tregs), which maintain immune homeostasis and prevent autoimmune and chronic inflammatory disease, but in patients with PM and DM there was no numerical deficit in Tregs [50] . An alternative hypothesis is that Tregs are functionally deficient or that the inflammatory milieu in muscles does not allow Treg suppression, similar to the situation in RA [51] . When investigating muscle biopsies from patients with PM and DM before and after glucocorticoid therapy, both the overall T cell count and the Treg count were lower after therapy, while CD4 + CD28 null T cells were not reduced [45] . Taken together, further characterization of the T cell phenotype in individual patients seems to be important to achieve an improved understanding of the role of T cells in the pathogenesis of IIMs. Moreover, investigations using T cell targeting therapies seems to be indicated, with evaluation of the effects on both clinical outcome measures and on T cell phenotype in muscle tissue and in peripheral blood.
Cytokines, alarmins, prostaglandins and leukotrienes
The inflammatory cells that are present in the muscle tissue may not only have direct effects on muscle fibres, but may also act through molecules that are produced and secreted. In addition, these molecules may also affect T cell activation and proliferation. Importantly, muscle fibres and endothelial cells may also be the source of such molecules. Several descriptive studies reported the presence of proinflammatory molecules in muscle tissue. Molecules of potential interest to target in patients with PM and DM are listed in Table 2 . To understand their function in PM and DM, their presence in muscle tissue could be correlated to the clinical phenotype and the effects on clinical symptoms by blocking of the molecule could be correlated to expression in muscle tissue and in blood. Another way to understand their role is to test their effects in experimental models. Importantly, several of the molecules that are produced in muscle have dual effects, as they may both support inflammation and induce muscle development and differentiation.
Cytokines
Type I IFNs are of specific interest in PM and DM as IFNs are strong inducers of MHC class I and class II molecules, a consistent aberrant phenotype on muscle fibres in these patients [59] . A type I IFN signature has been demonstrated both in muscle tissue and in peripheral blood [60] . Interestingly, circulating immune complex containing antibodies against RNA binding proteins, e.g. histidyltRNA synthetase can act as an endogenous type I IFN stimulating factor, as was reported in SLE [61] . Indeed, the sera from patients with anti-histidyl-tRNA synthetase antibodies (anti-Jo-1) have the potential to induce type I IFN [27] . These observations raise the possibility that different pathophysiological pathways may predominate in patients with different autoantibody profiles. Targeting type I IFN is an attractive future therapy to be tested in subsets of patients with anti-Jo-1 antibodies and in patients with an IFN signature. A phase I study targeting type I IFN by sifalimumab resulted in neutralization of an IFN signature in peripheral blood, supporting the role of type I IFN in this subset of patients with PM/DM [62] . Information on the autoantibody profile was not available in this report.
IL-1a and IL-1b expression is one of the most consistent cytokine patterns in the muscle tissue of patients with PM and DM. Treatment with the IL-1 receptor antagonist anakinra had a beneficial effect in one case with anti-Jo-1 antibodies [63] and in a series of patients with refractory PM and DM [64] . More information is needed on the effect of IL-1 blocking treatment in relation to myositis subphenotypes. Other cytokines or chemokines have not been associated with distinct autoantibody profiles or have not been investigated in this context. This might indicate that the cytokine and chemokine profile in the inflammatory muscle tissue may be a shared final molecular pathway independent of immune specificity.
The role of TNF in the pathogenesis in IIM is unclear, as TNF blockade has had varying effects and treatment with infliximab may even worsen the inflammation in treatmentresistant cases [65] . A recent report using etanercept in new-onset DM could demonstrate a glucocorticoid sparing effect [65, 66] . Thus TNF may have different roles in different subsets and phases of myositis disease. Another potential cytokine to target is IL-6, where two case reports have demonstrated a beneficial effect [67] . In addition, targeting IL-6 was efficient in a mouse model for myositis [68] . IL-18 is another molecule that has been demonstrated in muscle tissue and could be interesting to target by IL-18 blockade [69, 70] . IL-15 is a potentially interesting cytokine to target, as patients who had persisting IL-15 expression in muscle tissue after 6 months with conventional immunosuppressive treatment had a worse prognosis after 5 years follow-up compared with those that did not have IL-15 expression in the tissue after 6 months [42] . This could indicate a role of IL-15 in a subset of patients with a chronic course.
High mobility group box 1 (HMGB1) is an alarmin that can act with proinflammatory properties when released from macrophages or from cells undergoing necrosis [71] . HMGB1 is present with extranuclear and extracellular localization in muscle tissue from patients with PM/DM [72] . HMGB1 can up-regulate MHC class I in muscle fibres and can impair Ca 2+ release from the sarcoplasmic reticulum and thus cause impaired muscle contractility and weakness [73] . There was also persisting aberrant expression in muscle tissue after conventional immunosuppressive treatment in patients with persisting muscle weakness, making HMGB1 a potentially interesting target for blockade in myositis.
Other pathways that may have a role in the pathophysiology of PM and DM are the prostaglandin and leukotriene pathways, which are both up-regulated in the muscle tissue of myositis patients [74, 75] . In the context of immune mechanisms leukotriene B4 (LTB4) is interesting, as it may act as a link between the innate and adaptive immune responses [76] . It is a chemoattractant for activated T cells, inducing their migration into inflamed tissue, and is involved in the differentiation of naive murine T cells by inhibiting the differentiation of Tregs and promoting Th17 cells and can also augment cytokine production by activated T cells. Thus LTB4 could have a role in chronic inflammatory processes such as muscle inflammation. As there are drugs under development to specifically target prostaglandins and leukotrienes, these could be of interest for the treatment of myositis in the future.
Conclusion
In summary, there is clear evidence for a role of the adaptive immune system in the pathophysiology of PM and DM. This is based on evidence of T cells in the muscle tissue, a steady growing number of MSAs and by the HLA-DR region being a major genetic risk factor for IIMs. The specific targets of the immune reactions are still unclear, as the autoantibodies recognize ubiquitous autoantigens, and so far no muscle-specific autoantigens have been recognized in PM and DM. The T cells may directly cause muscle fibre cytotoxicity, both from the CD8 + T cells and through the CD28 null CD4 + and CD8 + T cells, which make them potentially interesting to target as therapy. T cells as well as other cells in the muscle tissue, both immune and non-immune cells, may also affect muscle fibre function indirectly by molecules released from these cells, such as cytokines, chemokines and leukotrienes, which can all be new targets for therapy. Importantly, different molecular pathways seem to predominate in different subsets of myosits. Novel ways to identify homogeneous subsets with linked pathways could be through subgrouping based on MSAs or by investigating molecular expression in muscle tissue before and after specific targeting therapies. A greater understanding of key molecular pathways will be important to develop new drugs for IIMs. As these are rare diseases, clinical trials will need to be performed in an international multicentre setting.
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